Latest News for APLIF
Appili adopts a new business strategy that focuses on the biodefence sector Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal…
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”),…
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for APLIF.
Senate Trading
No Senate trades found for APLIF.
U.S. House Trading
No House trades found for APLIF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.